Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

What’s Happening With Palantir Technologies (PLTR) Shares

Palantir Technologies Inc (NYSE: PLTR) shares are trading higher by 31.65% to $9.80 over the trailing five sessions after the company this week reported strong first-quarter results and said it expects to remain profitable each quarter through the
byHenry Khederian
May 11, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Palantir Technologies Inc (NYSE:PLTR) shares are trading higher by 31.65% to $9.80 over the trailing five sessions after the company this week reported strong first-quarter results and said it expects to remain profitable each quarter through the end of the year.

The stock also received a number of analyst rating updates following the earnings print.

What Happened?

Palantir Technologies reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of 4 cents.

The company also reported quarterly sales of $525.19 million which beat the analyst consensus estimate of $505.60 million by 3.9%. This sales figure is a 17.7% increase over sales of $446.36 million in the same period last year.

U.S. revenue grew 23% year-over-year. Commercial revenue was up 15%, and government revenue climbed 20%. Palantir’s total customer count increased 41% year-over-year. U.S customers jumped 50%…Read More

According to data from Benzinga Pro, PLTR has a 52-week high of $11.62 and a 52-week low of $5.92.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Halozyme Discloses That Bristol Myers Squibb Received Updated Action Date From U.S. FDA For Subcutaneous Nivolumab Co-Formulated with ENHANZE (Halozyme’s Proprietary Recombinant Human Hyaluronidase Enzyme); The Updated Goal Date Is December 29, 2024

By Benzinga Newsdesk
May 21, 7:55 AM
Halozyme announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous

HALO

Read More

ONE Store Secures $10M Investment From Digital Turbine, Bringing Digital Turbine’s Innovative SingleTap Technology To Over 40M+ ONE Store Users In South Korea, And Joining Forces In Bringing One Store’s App Marketplace To Key Markets Overseas

By Benzinga Newsdesk
February 6, 9:24 AM
- Global mobile growth leader Digital Turbine invests in ONE Store, acknowledging its potential for global expansion beyond the Korean market.- Both companies will concentrate their collaborative efforts on advancing ONE

APPS

Read More

Regeneron Pharmaceuticals Announced 63% Combined Pathologic Response Rate for Neoadjuvant Libtayo Monotherapy in Stage II to IV Resectable CSCC Per Primary Analysis of a Confirmatory Phase 2 Trial; Data Presented at ESMO

By Charles Gross
September 12, 4:58 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC).

REGN